Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma

Thyroid

Volumn 12, Issue 2, 2002, Pages 121-134

  Van Nostrand, Douglas ^a   Atkins, Frank ^a   Yeganeh, Fred ^a   Acio, Elmo ^a   Bursaw, Randy ^a   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

BONE MARROW DEPRESSION; DOSE RESPONSE; DOSIMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; PNEUMONIA; PRIORITY JOURNAL; REMISSION; REVIEW; SALIVARY GLAND DISEASE; SURVIVAL RATE; THYROID CARCINOMA; TREATMENT OUTCOME;

EID: 0036122254     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072502753522356     Document Type: Review

References (64)

1. Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases: Statistics following University of Michigan therapy
2. Radioactive iodine therapy effect on functioning metastases of adenocarcinoma of the thyroid
3. The treatment of thyroid carcinoma with radioactive iodine
4. Radionuclide diagnosis and therapy of thyroid cancer: Current Status Re]port
5. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer
6. Radioiodine I-131 therapy in the management of thyroid cancer
7. I-131 therapy in differentiated thyroid carcinoma
8. Treatment of thyroid cancer
9. Thyroid cancer
10. The role of TRH and lithium in the management of thyroid cancer
11. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma
12. "High-Dose" radioiodine therapy in advanced differentiated thyroid carcinoma
13. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer
14. In vivo quantitation of lesion radioactivity using external counting methods
15. International Commission on Radiological Protection Radionuclide Transformations
16. Dosage determination with radioactive isotopes. II. Practical considerations in therapy and protection
17. Internally administered radioisotopes
18. Chapter 9: Radioactive Nuclides in Medicine and Biology
19. Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distribution in solid tumors
20. S absorbed dose per unit cumulated activity for selected radionuclides and organs
21. International Radionuclide radiation dosimetry: A review of basic concepts and recent developments
22. 131I treatment of thyroid cancer
23. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131
24. Treatment of metastatic thyroid cancer
25. A comparison of methods for assessing patient body burden following I-131 therapy for thyroid cancer
26. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer
27. Patient-specific wholebody dosimetry: Principles and a simplified method for clinical implementation
28. Comparison of total body dosimetry predicted with gammacamera whole-body scans versus collimated probe for patients receiving I-131 anti-B1 antibody
29. Thyroid cancer dosimetry using clearance fitting
30. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer
31. Validation study to determine if accurate dosimetry for radioiodine therapy for thyroid cancer can be performed using only external counting data
32. Absorbed doses in the marrow during I131 therapy
33. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
34. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma
35. Thyroid Carcinoma with high levels of function: Treatment with 1-131
36. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer
37. Measurement of dose during radioiodine treatment of thyroid cancer
38. Iodine 131 Treatment of thyroid cancer: Absorbed dose calculated from post-therapy scans
39. Radiation dose assessments in radioiodine (I-131) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid
40. A unified approach to photon and beta particle dosimetry
41. Radiation dose rate: A factor of importance in radiobiology and radiotherapy
42. Radiation dose assessments in radioiodine (I-131) therapy. 1. The necessity for in-vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid
43. Radioiodine therapy of thyroid cancer
44. Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodides I-131
45. Bone metastases of thyroid cancer, biological behavior and therapeutic possibilities
46. Prospects from the treatment of thyroid carcinoma with radioiodine
47. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer
48. Radioiodine-131 therapy for well differentiated thyroid cancer-A quantitative radiation dosimetric approach: Outcome and validation in 85 patients
49. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well differentiated thyroid cancer
50. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer
51. Thyroid cancer
52. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma
53. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades
54. Radioiodine treatment of thy]roid cancer: General considerations-II: Side effects of radioiodine therapy for thyroid cancer
55. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma
56. Side effects of "rational dose" iodine-131 therapy for metastatic well differentiated thyroid carcinoma
57. De]termination of iodine-131 diagnostic dose for imaging metastatic thyroid cancer
58. Lithium as a potential adjuvant to I-131 therapy of metastatic, well-differentiated thyroid carcinoma
59. The changing role of radioiodine in the management of differentiated thyroid cancer
60. An approach to the management of patients with scan negative, thyroglobulin positive, differenti]ated thyroid cancer
61. Therapeutic Dose of Iodine-131 Reveal Undiagnosed Metastases in Thyroid Cancer Patients with Detectable Serum Thyroglobulin Levels
62. Iodine 131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan
63. I-131 therapy for elevated thyroglobulin levels
64. Serum Thyroglobulin Determination in the Follow-up of Patients with Differentiated Thyroid Carcinoma